AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 211 min read$SMMT

Summit Therapeutics Inc. (SMMT) Collaborates With ECOG-ACRIN on Phase II/III BTC Trial

Summit Therapeutics (SMMT) partners with ECOG-ACRIN for a Phase II/III trial of ivonescimab plus chemo against pembrolizumab or durvalumab plus chemo for advanced biliary tract cancer. The trial is expected to start in Q4 2026, following positive data from China. This expands ivonescimab's potential beyond NSCLC.

Original reporting
tradingview.com
Published Oct 21, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Summit Therapeutics Inc. (SMMT) Collaborates With ECOG-ACRIN on Phase II/III BTC Trial — source image
Source · tradingview.com
Decision brief

The 30-second read

$SMMTBullishMed
01

Why it matters

The partnership with ECOG-ACRIN adds credibility and may accelerate data readouts, influencing valuation.

02

Market read

First report of a pivotal trial collaboration that could serve as a catalyst for Summit Therapeutics' stock.

03

What to watch

Regulatory timelines and competition from other BTC therapies could moderate the upside.

Relevance 8/10Novelty 8/10Timing: pre‑market Q4 2026 activation

Background

Summit Therapeutics (SMMT) is expanding its ivonescimab program beyond NSCLC into biliary tract cancer with a U.S. registration‑enabling study.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

Summit Therapeutics announced a new Phase II/III collaboration with ECOG-ACRIN to test ivonescimab in advanced biliary tract cancer.

Expected impact

likely upward pressure as investors price in the potential pivotal trial data

Evidence & confidence

First disclosure of a late‑stage trial for a biotech with no prior U.S. data; material catalyst for valuation.

Market effects

Sector

May boost sentiment for the broader biliary tract cancer and oncology biotech sector.

Regional

Limited to U.S. biotech investors; no immediate regional effect.

Global

Potentially relevant to global oncology research community but limited direct market impact.

Counterpoint

What could challenge this read

If the trial fails to meet endpoints, the stock could face sharp downside.

Key entities

  • company
    Summit Therapeutics Inc.

    Biotech developer of ivonescimab.

  • organization
    ECOG-ACRIN

    U.S. clinical trial network collaborating on the BTC study.

Read at source← All news

StorySummit Therapeutics partners with ECOG‑ACRIN on registration‑enabling Phase II/III biliary tract cancer trial

Related articles

OCT 21
$SMMTMedAI 8/10

Summit Therapeutics (SMMT) Partners with ECOG-ACRIN for Phase II

Summit Therapeutics (SMMT) partners with ECOG-ACRIN to start a Phase II/III trial for ivonescimab in advanced biliary tract cancer. The study will compare ivonescimab plus chemotherapy against standard immunotherapy regimens. Summit's P/S ratio is 560.0x, reflecting high growth expectations. Insider buying totals $114.6M over the past year. The company's GF Score is 29, indicating challenges in profitability and growth.

gurufocus.com3 min
OCT 21
$SMMTMed

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Summit Therapeutics (SMMT) and ECOG-ACRIN will collaborate on a Phase II/III trial of ivonescimab for biliary tract cancer, starting in Q4 2026. The study will compare ivonescimab with chemotherapy against pembrolizumab or durvalumab plus chemotherapy. Ivonescimab is a bispecific antibody targeting PD-1 and VEGF, with prior positive Phase III results in China. Summit aims to expand ivonescimab's development in areas of high unmet need.

finanznachrichten.de2 min
OCT 19
$SMMTMed

Summit Therapeutics Announces Opening of Global Phase II Study o

Summit Therapeutics (NASDAQ: SMMT) and Akeso Inc. opened a Phase II study of ivonescimab, a PD-1/VEGF bispecific antibody, for advanced kidney cancer. The study will enroll 100 patients in the U.S. and China, testing ivonescimab in combination with other treatments. Summit aims to evaluate the drug's efficacy in untreated, incurable cases. Ivonescimab is also being studied in other cancers, with multiple Phase III trials ongoing.

gurufocus.com2 min
OCT 19
$SMMTMedAI 8/10

Summit Therapeutics (SMMT) Launches Phase II Trial for Ivonescim

Summit Therapeutics (SMMT) began Phase II trials for ivonescimab, a bispecific antibody for advanced clear cell renal cell carcinoma. The company trades at a high P/S ratio, reflecting market expectations for future growth, despite no current revenue. Insiders have bought $114.6 million in shares, signaling confidence. Summit has a GF Score of 29/100, indicating challenges in profitability and growth but moderate financial strength.

gurufocus.com2 min
OCT 19
$SMMTMedAI 8/10

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

Summit Therapeutics (NASDAQ: SMMT) and Akeso Inc. (HKEX: 9926) launched a global Phase II study (SMT112-216) of ivonescimab in advanced clear cell renal cell carcinoma (ccRCC). The trial will evaluate ivonescimab alone and in combination with cadonilimab or ipilimumab in 100 patients across the U.S. and China. Ivonescimab is a novel PD-1/VEGF bispecific antibody. Summit aims to assess its efficacy in untreated advanced ccRCC, a common kidney cancer type with limited late-stage treatment options.

finance.yahoo.com2 min